Rhumbline Advisers Gt Biopharma, Inc. Transaction History

Rhumbline Advisers

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$1.64 - $3.11 $26,382 - $50,030	-16,087 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$2.6 - $3.3 $1,562 - $1,983	-601 Reduced 3.6%	16,087 $46,000
Q3 2021 Nov 12, 2021	SELL	$6.68 - $15.26 $12,999 - $29,695	-1,946 Reduced 10.44%	16,688 $112,000
Q2 2021 Aug 05, 2021	BUY	$7.19 - $18.96 $133,978 - $353,300	18,634 New	18,634 $289,000

564

Ticker GTBP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,557,700
Market Cap $96.4M
Description
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate th...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.